New research has identified a protein that could serve as both a biomarker and therapeutic target to weaken stem-like cancer ...

Targeting the WNT signaling pathway represents a promising strategy for cancer therapy. The field has evolved to include numerous inhibitors currently under preclinical and clinical investigation.

Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most important ...

Cancer cells can disarm the immune system not just by hiding from it, but by actively reprogramming nearby immune cells into ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient ...

Preclinical research across multiple cancer types now shows that the NAD+ salvage pathway, the same biological mechanism targeted by popular anti-aging supplements like nicotinamide mononucleotide ...

“Aspirin is a drug that is readily available globally and extremely inexpensive compared to many modern cancer drugs, which ...

Aspirin reduces the risk of colon cancer recurrence after surgery, but only in patients with a specific genetic marker ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.